Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly

Pei-Chun Chan, Pin-Hui Lee, Min-Ju Lu, You-Chieh Huang, Teng-Yi Feng, Wen-Wen Chen, Chia-Chi Lee, Yen-Fang Huang, Chen-Yuan Chiang
European Respiratory Journal 2019 53: 1802396; DOI: 10.1183/13993003.02396-2018
Pei-Chun Chan
1Division of Chronic Infectious Disease, Centers for Disease Control, Taipei, Taiwan
2Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
3Dept of Pediatrics, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pcanita.tw@cdc.gov.tw
Pin-Hui Lee
1Division of Chronic Infectious Disease, Centers for Disease Control, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min-Ju Lu
1Division of Chronic Infectious Disease, Centers for Disease Control, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
You-Chieh Huang
1Division of Chronic Infectious Disease, Centers for Disease Control, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teng-Yi Feng
1Division of Chronic Infectious Disease, Centers for Disease Control, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wen-Wen Chen
4Taiwan Drug Relief Foundation, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chia-Chi Lee
1Division of Chronic Infectious Disease, Centers for Disease Control, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yen-Fang Huang
1Division of Chronic Infectious Disease, Centers for Disease Control, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chen-Yuan Chiang
5Division of Pulmonary Medicine, Dept of Internal Medicine, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan
6Division of Pulmonary Medicine, Dept of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
7International Union against Tuberculosis and Lung Disease, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Our experience has shown that with proper support and medical care under programmatic conditions, it is feasible to achieve a high completion rate of 3HP even among the elderly http://ow.ly/o3ED30nQfRx

To the Editor:

Management of latent tuberculosis infection (LTBI) is a core intervention in the pursuit of tuberculosis (TB) elimination and is one of the eight activities recommended by the World Health Organization [1]. We read with great interest the paper by Gao et al. [2] investigating two short-course regimens with rifapentine plus isoniazid for the treatment of LTBI in Chinese patients aged 50–70 years. They reported that due to the ever-increasing occurrence of adverse events, the 3-month once-weekly regimen and the 2-month twice-weekly regimen were truncated to 8 and 6 weeks, respectively. Gao et al. [2] concluded that the short regimens tested must be used with caution among the elderly because of a high frequency of adverse events. The findings reported by Gao et al. [2] were not consistent with our experience in Taiwan.

The use of 3-month once-weekly rifapentine plus isoniazid (3HP) for the treatment of LTBI in Taiwan began with two pilot studies that enrolled contacts of TB patients [3, 4]. Subsequently, the LTBI Treatment for All Contacts Program was initiated in 2016, providing 3HP as well as 9-month-isoniazid (9H) for the treatment of LTBI among contacts aged 12 years or older with directly observed preventive therapy. 3HP was endorsed by the Taiwan Centers for Disease Control [5], although at that time rifapentine was not yet approved by the Taiwan Food and Drug Administration [6].

We closely monitored adverse events and reasons for the discontinuation of LTBI treatment were entered into the electronic TB case management system by public health nurses. Serious adverse events were defined as any hospitalisation, emergency department visit for more than 24 h or death during treatment. We reviewed case management records and medical charts to estimate serious adverse events associated with 3HP using the Modified Naranjo Adverse Drug Reaction Probability Scale [7].

Between April 2016 and June 2018, a total of 14 676 individuals received treatment of LTBI, of whom 7974 (54%) were aged 50 years or older. Of the 7974 individuals, 5087 (63.8%) preferred 3HP and 2887 preferred 9H. The proportion of individuals with early termination of treatment due to adverse events in those who were treated with 3HP was lower than that with those treated with 9H (8.0% (409/5087) versus 9.4% (272/2887); p=0.03). The most frequently encountered adverse events leading to permanent discontinuation differed between the two regimens. Among patients who terminated 3HP early, 30% discontinued treatment due to fever; among patients who terminated 9H early, 53% discontinued due to drug-induced hepatitis. 85 (0.84%) patients treated with 3HP had serious adverse events and permanently discontinued 3HP, mainly due to flu-like illness (53%), hypersensitivity (24%) and hepatotoxicity (18%). No death or long-term sequelae associated with 3HP was observed.

We analysed completion of LTBI treatment among 4172 individuals aged 50 years and older who had LTBI treatment initiated between April 2016 and July 2017 (table 1). Those who received 3HP had a higher treatment completion rate compared to those receiving 9H (83.9% versus 78.8%; p<0.001). Gao et al. [2] reported that 1% of those who received 3HP had drug-induced hepatotoxicity leading to permanent discontinuation of treatment after 8 weeks. This figure was found to be 0.8% in our study cohort and no fulminant hepatic failure was noted.

View this table:
  • View inline
  • View popup
TABLE 1

Treatment outcome of latent tuberculosis infection for those aged 50 years and older

Drug quality may be associated with adverse events. Currently, isoniazid used in Taiwan is generic and is domestically produced by pharmaceutic companies with good manufacturing practice following a pharmaceutical inspection co-operation scheme. Rifapentine (Priftin) was purchased from Sanofi produced in Italy. Since the study was discontinued early, we wonder to what extent a high frequency of adverse events observed by Gao et al. [2] were due to the drugs that they used among rural residents in Zhongmu County, China. Furthermore, tolerability of treatment of LTBI could be relatively low because the subjects in Zhongmu did not have clinical symptoms as severe as hepatic failure. Gao et al. [2] did not use 9H and were not able to assess tolerability of 9H in their study population. Thus, it is not clear to what extent tolerability of LTBI treatment itself has contributed to the challenge of completing 3HP treatment.

It has been reported that age is associated with adverse events and the elderly are more likely to experience adverse events during the treatment of LTBI, regardless of the regimens used [4, 8]. However, our experience has shown that with proper support and medical care under programmatic conditions, it is feasible to achieve a high completion rate of 3HP, even among the elderly [4, 9]. Treatment of LTBI among the elderly to mitigate the risk of developing active TB is crucial in settings where TB burden is disproportionally high among the elderly [10]. Our experience shows that the use of 3HP for the treatment of LTBI is a useful tool for achieving the goals of the “The End TB Strategy” and, hopefully, in eliminating TB.

Footnotes

  • Conflict of interest: P-C. Chan has nothing to disclose.

  • Conflict of interest: P-H. Lee has nothing to disclose.

  • Conflict of interest: M-J. Lu has nothing to disclose.

  • Conflict of interest: Y-C. Huang has nothing to disclose.

  • Conflict of interest: T-Y. Feng has nothing to disclose.

  • Conflict of interest: W-W. Chen has nothing to disclose.

  • Conflict of interest: C-C. Lee has nothing to disclose.

  • Conflict of interest: Y-F. Huang has nothing to disclose.

  • Conflict of interest: C-Y. Chiang has nothing to disclose.

  • Received December 17, 2018.
  • Accepted February 14, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence

Reference

  1. ↵
    1. Lönnroth K,
    2. Migliori GB,
    3. Abubakar I, et al.
    Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928–952.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Gao L,
    2. Zhang H,
    3. Xin H, et al.
    Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J 2018; 52: 1801470.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Huang YW,
    2. Yang SF,
    3. Yeh YP, et al.
    Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan. Medicine (United States) 2016; 95: e4126.
    OpenUrl
  4. ↵
    1. Sun HY,
    2. Huang YW,
    3. Huang WC, et al.
    Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: a multicentre randomised controlled trial in Taiwan. Tuberculosis (Edinb) 2018; 111: 121–126.
    OpenUrl
  5. ↵
    1. Centers for Disease Control and Prevention
    . Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011; 60: 1650–1653.
    OpenUrlPubMed
  6. ↵
    Food and Drug Administration, Ministry of Health and Welfare, Taiwan. The content of license for Priftin 150mg film-coated tablets. www.fda.gov.tw/MLMS/H0001D.aspx?Type=Lic&LicId=52027203 Date last updated: July 28, 2017. Date last accessed: Feb 11, 2019.
  7. ↵
    1. Sterling TR,
    2. Moro RN,
    3. Borisov AS, et al.
    Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study. Clin Infect Dis 2015; 61: 527–535.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Kunst H,
    2. Khan KS
    . Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 2010; 14: 1374–1381.
    OpenUrlPubMedWeb of Science
  9. ↵
    1. Sandul AL,
    2. Nwana N,
    3. Holcombe JM, et al.
    High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent Mycobacterium tuberculosis infection. Clin Infect Dis 2017; 65: 1085–1093.
    OpenUrl
  10. ↵
    1. Houben RM,
    2. Dodd PJ
    . The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med 2016; 5: 1–13.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 53 Issue 3 Table of Contents
European Respiratory Journal: 53 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly
Pei-Chun Chan, Pin-Hui Lee, Min-Ju Lu, You-Chieh Huang, Teng-Yi Feng, Wen-Wen Chen, Chia-Chi Lee, Yen-Fang Huang, Chen-Yuan Chiang
European Respiratory Journal Mar 2019, 53 (3) 1802396; DOI: 10.1183/13993003.02396-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly
Pei-Chun Chan, Pin-Hui Lee, Min-Ju Lu, You-Chieh Huang, Teng-Yi Feng, Wen-Wen Chen, Chia-Chi Lee, Yen-Fang Huang, Chen-Yuan Chiang
European Respiratory Journal Mar 2019, 53 (3) 1802396; DOI: 10.1183/13993003.02396-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • Reference
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Rifapentine access in Europe: concerns over key TB treatment
  • P. aeruginosa membrane vesicles cause endothelial barrier failure
  • Mortality after admission with pneumonia higher than after admission with COPD exacerbation
Show more Agora

Correspondence

  • Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside
  • Liver cancer in severe alpha-1 antitrypsin deficiency: Who is at risk?
  • Cancer risk in severe alpha-1-antitrypsin deficiency - the importance of the early identification
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society